(Reuters) -Billionaire Ken Griffin's hedge fund Citadel has taken a short position in British drugmaker GSK , the Financial Times reported on Friday. Citadel has taken a short position worth 305 ...

Drug developer GSK is vacating its 635,000-square-foot life sciences lab in Rockville, Maryland, where it was the sole tenant ...

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has bee ...

UBS analyst Jo Walton maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of p1,580.00. The company’s shares opened today at p1,392.50. According ...

New shares at such a low price could add value to my existing holding in GSK. But I need to check that there is value in the stock. Such a fall could also indicate that the company is simply worth ...

With California wildfires triggering a massive rebuilding process that could take several years, investors are looking closer at lumber stocks. Amid controversy over climate-risk disclosure rules ...

GSK Insurance Brokers, formerly known as Graham S Knight & Associates Insurance Brokers, is an insurance broker with a client base that stretches Australia wide. Its team of corporate brokers is ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares closed last Friday at p1,359.00.

The company is planning to test higher doses of the drug ... Both assets are poised to enter registrational studies under accelerated approval pathways, according to Jefferies. GSK to Stay Out of ...

GSK adds that the strength of these will overcome short-term vaccine challenges from external pressures in the US and China. The Brentford, U.K.-based company remains confident that Arexvy ...